titlesubmit dateissue date
Now showing items 1-9 of 9
FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy.
Histology-dependent prognostic role of pERK and p53 protein levels in early-stage non-small cell lung cancer
Impact of DLK1-DIO3 imprinted cluster hypomethylation in smoker patients with lung cancer.
Impact of Heat Shock Protein 90 Inhibition on the Proteomic Profile of Lung Adenocarcinoma as Measured by Two-Dimensional Electrophoresis Coupled with Mass Spectrometry
Inflammation and stem markers association to PIM1/PIM2 kinase-induced tumors in breast and uterus
MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma
Prognostic Role of the FGFR4-388Arg Variant in Lung Squamous-Cell Carcinoma Patients With Lymph Node Involvement
Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor.
The FGFR4-388arg Variant Promotes Lung Cancer Progression by N-Cadherin Induction